GLIVEC 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

( ARTG ) GLIVEC is indicated for the: -Treatment of patients with chronic myeloid leukaemia (CML).‍‍‍‍‍‍​​​‍​​​​​​ -Treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. -Treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy. -Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed. -Treatment of adult patients with aggressive systemic mastocytosis (ASM) where conventional therapies have failed. Treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL). -Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) -Adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (See Dosage and Administration and Clinical Trials) . -Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)GLIVEC is indicated for the: -Treatment of patients with chronic myeloid leukaemia (CML). -Treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. -Treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy. -Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed. -Treatment of adult patients with aggressive systemic mastocytosis (ASM) where conventional therapies have failed. Treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL). -Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) -Adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (See Dosage and Administration and Clinical Trials). -Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).